Streetbeat News

Stock Prices

MNST

Monster Beverage (NASDAQ:MNST) has significantly outperformed the market over the past decade, delivering an average annual return of 15.52%. A $100 investment in MNST 10 years ago would be worth $417.84 today. The company's current market capitalization is $48.74 billion.

Portfolio Pulse from Benzinga Insights

June 24, 2024 | 6:00 pm

JLL

Jones Lang LaSalle (NYSE:JLL) has outperformed the market over the past 20 years with an average annual return of 10.69%, surpassing the market by 2.51% annually. A $1000 investment in JLL 20 years ago would be worth $7,633.21 today. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

June 24, 2024 | 6:00 pm

AAPL

AMD

AVGO

GOOGL

INTC

META

MRVL

MSFT

NVDA

ORCL

Nvidia is dominating the GPU market as generative AI adoption grows, with nearly half of enterprises implementing GenAI. Microsoft and OpenAI are seen as the most strategic AI vendors, while interest in Google Cloud, Meta, and Oracle is increasing. Nvidia leads the GPU market with over 70% share, followed by AMD and Intel. Broadcom is the leader in networking for enterprise adoption. Apple devices are expected to grow in enterprise use.

Portfolio Pulse from Anusuya Lahiri

June 24, 2024 | 5:59 pm

BTCUSD

ETHUSD

10x Research has raised concerns about Bitcoin's price trajectory, suggesting a potential significant downturn due to a possible double top formation and several bearish factors. Bitcoin ETFs have seen $1.2 billion in net outflows, and large-scale liquidations in Bitcoin and Ethereum futures markets have occurred. Declining Bitcoin miner revenue and low Ethereum network activity also contribute to the bearish outlook.

Portfolio Pulse from Murtuza Merchant

June 24, 2024 | 5:55 pm

IBM

Goldman Sachs analyst James Schneider has initiated coverage on IBM with a Buy rating and a price target of $200. Schneider believes the current cyclical correction in the IT sector, driven by IT spending constraints and a shift towards AI-focused CapEx, presents an opportunity for IBM. Despite concerns about Generative AI's impact on the IT Services sector, Schneider is optimistic about IBM's potential to gain market share. IBM's dividend yield is 4.24%, and the company has buyback programs that support its share price.

Portfolio Pulse from Anusuya Lahiri

June 24, 2024 | 5:52 pm

MSFD

MSFT

MSFU

NVDA

Microsoft (MSFT) and Nvidia (NVDA) show contrasting performances, with MSFT holding steady and NVDA dropping 5%. This impacts Direxion's leveraged ETFs: MSFU (bullish on MSFT) and MSFD (bearish on MSFT). MSFU has gained 30% YTD, while MSFD has lost 17%. Investors should consider these ETFs for short-term trades.

Portfolio Pulse from Joshenomoto@benzinga.com

June 24, 2024 | 5:52 pm

NNE

Nano Nuclear Energy Inc (NASDAQ:NNE) shares surged by 37.8% to $21.69 after the company acquired intellectual property for an annular linear induction pump used in small nuclear reactor cooling and heat transfer. Dr. Carlos O. Maidana will collaborate as a consultant to further develop this technology, aiming for SBIR Phase III Award status.

Portfolio Pulse from Henry Khederian

June 24, 2024 | 5:50 pm

KORE

KORE Group Holdings Inc (NASDAQ:KORE) shares are down 16.8% to $0.49 after announcing a 1-for-5 reverse stock split to meet NYSE's minimum listing requirements. The split, effective July 1, aims to increase the stock's per share price. KORE shares have decreased by 64.28% in the past year and have a 52-week high of $1.59 and a low of $0.32.

Portfolio Pulse from Henry Khederian

June 24, 2024 | 5:49 pm

MKSI

MKS Instruments (NYSE:MKSI) has seen a 28.68% rise in its short percent of float, now at 6.55%. This indicates increased bearish sentiment, although it has less short interest compared to its peers. It would take traders 3.98 days to cover their short positions.

Portfolio Pulse from Benzinga Insights

June 24, 2024 | 5:45 pm

ELV

UNH

Morgan Stanley has initiated coverage on Elevance Health Inc (NYSE:ELV) with an Overweight rating and a price target of $643, citing its diversified portfolio and undervaluation. Despite challenges in Medicare Advantage, Elevance's resilience and growth potential in segments like Pharmacy Benefit Management and Carelon Services are highlighted. Elevance's shares have risen 13.3% year-to-date, trading at a P/E ratio of 13.6 times, slightly below its diversified peers.

Portfolio Pulse from Vandana Singh

June 24, 2024 | 5:45 pm